Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 281 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2017  |  Volume : 21  |  Issue : 1  |  Page : 210-230

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
3 Department of Endocrinology and Metabolic Diseases, Post Graduate Medical Institute, Hayatabad Medical Complex, Peshawar, Pakistan
4 Department of Endocrinology, BIRDEM and Ibrahim Medical College, Dhaka, Bangladesh
5 Department of Medicine, MLN Medical College, Allahabad, Uttar Pradesh, India
6 Department of Endocrinology, Excel Centre Hospitals, Guwahati, Assam, India
7 Department of Endocrinology, Colombo South Teaching Hospital, Colombo, Sri Lanka
8 Department of Medicine, Pondicherry Institute of Medical Sciences, Puducherry, India
9 BP Koirala Institute of Health Sciences, Dharan, Nepal
10 Department of Medicine, National Institute of Cardiovascular Diseases, Karachi, Pakistan
11 Department of Endocrinology, Asgar Ali Hospital, Dhaka, Bangladesh
12 Department of Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan
13 Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India
14 Diabetes, Thyroid and Endocrinology Care Centre, Kopundole, Nepal
15 Department of Endocrinology, Norvic Hospital, Kathmandu, Nepal
16 Department of Endocrinology, National Hospital of Sri Lanka, Colombo, Sri Lanka
17 Department of Endocrinology, Teaching Hospital Karapitiya, Galle, Sri Lanka
18 Department of Endocrinology, Chellaram Institute of Diabetes, Pune, Maharashtra, India

Correspondence Address:
Sanjay Kalra
Bharti Hospital, Karnal - 132 001, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.196029

Rights and Permissions

Diabetes prevalence shows a continuous increasing trend in South Asia. Although well-established treatment modalities exist for type 2 diabetes mellitus (T2DM) management, they are limited by their side effect profile. Sodium–glucose co-transporter 2 inhibitors (SGLT2i) with their novel insulin-independent renal action provide improved glycemic control, supplemented by reduction in weight and blood pressure, and cardiovascular safety. Based on the clinical outcomes with SGLT2i in patients with T2DM, treatment strategies that make a “good clinical sense” are desirable. Considering the peculiar lifestyle, body types, dietary patterns (long duration religious fasts), and the hot climate of the South Asian population, a unanimous decision was taken to design specific, customized guidelines for T2DM treatment strategies in these regions. The panel met for a discussion three times so as to get a consensus for the guidelines, and only unanimous consensus was included. After careful consideration of the quality and strength of the available evidence, the executive summary of this consensus statement was developed based on the American Association of Clinical Endocrinologists/American College of Endocrinology protocol.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded565    
    Comments [Add]    
    Cited by others 1    

Recommend this journal